Doxycycline plus ivermectin versus ivermectin alone for treatment of patients with onchocerciasis

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 1, 2016, Pages

  Abegunde, Ayokunle T ^a   Ahuja, Richard M ^a   Okafor, Nkem J ^b  

^a Jr Hospital of Cook County   (United States)

^b Kaplan Medical   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; IVERMECTIN; LIVER ENZYME; ANTIFILARIAL AGENT;

ANTIMICROBIAL THERAPY; ARTHRALGIA; BLOODY DIARRHEA; COMPARATIVE EFFECTIVENESS; DIARRHEA; ENZYME BLOOD LEVEL; EPIDEMIOLOGICAL DATA; EYE INJURY; FEVER; HEADACHE; HUMAN; INFECTION PREVENTION; NAUSEA AND VOMITING; ONCHOCERCIASIS; OUTCOME ASSESSMENT; PAIN; PHOTOSENSITIVITY; PREVALENCE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; VERTIGO; VISION; COMBINATION DRUG THERAPY; META ANALYSIS; ONCHOCERCIASIS, OCULAR; VISION DISORDERS;

DOXYCYCLINE; DRUG THERAPY, COMBINATION; FILARICIDES; HUMANS; IVERMECTIN; ONCHOCERCIASIS; ONCHOCERCIASIS, OCULAR; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VISION DISORDERS;

EID: 84966293178     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD011146.pub2     Document Type: Review

References (44)

1. Hoerauf A, Specht S, Büttner M, Pfarr K, Mand S, Fimmers R, et al. Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study. Medical Microbiology and Immunology 2008;197(3):295-311.
2. Masud H, Qureshi TQ, Dukley M. Effects of ivermectin with and without doxycycline on clinical symptoms of onchocerciasis. Journal of the College of Physicians and Surgeons Pakistan 2009;19(1):34-8.
3. Turner JD, Tendongfor N, Esum M, Johnston KL, Langley RS, Ford L, et al. Macrofilaricidal activity after doxycycline only treatment of Onchocerca volvulus in an area of Loa loa co-endemicity: a randomized controlled trial. PLOS Neglected Tropical Diseases 2010;4(4):e660.
4. Hoerauf A, Mand S, Fischer K, Kruppa T, Marfo-Debrekyei Y, Debrah AY, et al. Doxycycline as a novel strategy against bancroftian filariasis-depletion of Wolbachia endosymbionts from Wuchereria bancrofti and stop of microfilaria production. Medical Microbiology and Immunology 2003;192(4):211-6.
5. Tamarozzi F, Tendongfor N, Enyong PA, Esum M, Faragher B, Wanji S, et al. Long term impact of large scale community-directed delivery of doxycycline for the treatment of onchocerciasis. Parasites & Vectors 2012;5(53):1-5.
6. Bailey IL, Lovie JE. New design principles for visual acuity letter charts. American Journal of Optometry and Physiological Optics 1976;53(11):740-5.
7. Baker RH, Abdelnur OM. Onchocerciasis in Sudan: the distribution of the disease and its vectors. Tropical Medicine and Parasitology 1986;37(4):341-55.
8. Boatin BA, Richards FO. Control of onchocerciasis. Advances in Parasitology 2006;61:349-94.
9. Burnham G. Onchocerciasis. Lancet 1998;351(9112):1341-6.
10. Centers for Disease Control and Prevention. Onchocerciasis: diagnosis. www.cdc.gov/parasites/onchocerciasis/diagnosis.html (accessed 14 March 2014).
11. Cooper PJ, Guderian RH, Proaño R, Taylor DW. Absence of cellular responses to a putative autoantigen in onchocercal chorioretinopathy. Cellular autoimmunity in onchocercal chorioretinopathy. Investigative Ophthalmology and Visual Science 1996;37(2):405-12.
12. Cooper PJ, Guderian RH, Proaño R, Taylor DW. The pathogenesis of chorioretinal disease in onchocerciasis. Parasitology Today 1997;13(3):94-8.
13. Ejere HOD, Schwartz E, Wormald R, Evans JR. Ivermectin for onchocercal eye disease (river blindness). Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD002219.pub2]
14. Enk CD. Onchocerciasis - river blindness. Clinics in Dermatology 2006;24(3):176-80.
15. Gardon J, Gardon-Wendel N, Demanga N, Kamgno J, Chippaux JP, Boussinesq M. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet 1997;350(9070):18-22.
16. GRADEpro GDT. GRADEpro Guideline Development Tool [Software]. McMaster University (developed by Evidence Prime, Inc, 2015). Available from www.gradepro.org.
17. Higazi TB, Filiano A, Katholi CR, Dadzie Y, Remme JH, Unnasch TR. Wolbachia endosymbiont levels in severe and mild strains of Onchocerca volvulus. Molecular and Biochemical Parasitology 2005;141(1):109-12.
18. Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
19. Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
20. Hise AG, Daehnel K, Gillete-Ferguson I, Cho E, McGarry HF, Taylor MJ, et al. Innate immune responses to endosymbiotic Wolbachia bacteria in Brugia malayi and Onchocerca volvulus are dependent on TLR2, TLR6, MyD88 and Mal, but not TLR4, TRIF, or TRAM. Journal of Immunology 2007;178(2):1068-76.
21. Hoerauf A, Specht S, Marfo-Debrekyei Y, Buttner M, Debrah AY, Mand S, et al. Efficacy of 5-week doxycycline treatment on adult Onchocerca volvulus. Parasitology Research 2009;104(2):437-47.
22. Hopkins A. Onchocerciasis. In: Johnson GJ, Minassian DC, Weale RA, West SK editor(s). The Epidemiology of Eye Disease. 3rd Edition. London: Imperial College Press, 2012.
23. Johnson G, Minassian DC, Weale R, editors. The Epideimiology of Eye Disease. London: Chapman and Hall, 1998.
24. Little MP, Basanez MG, Breitling LP, Boatin BA, Alley ES. Incidence of blindness during the Onchocerciasis control programme in western Africa, 1971-2002. Journal of Infectious Diseases 2004;189(10):1932-41.
25. Mackenzie CD, Homeida MM, Hopkins AD, Lawrence JC. Elimination of onchocerciasis from Africa: possible?. Trends in Parasitology 2012;28(1):16-22.
26. Plaisier AP, van Oortmarssen GJ, Remme J, Habbema JD. The reproductive lifespan of Onchocerca volvulus in West African savanna. Acta Tropica 1991;48(4):271-84.
27. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
28. Saint André Av, Blackwell NM, Hall LR, Hoerauf A, Brattig NW, Volkmann L, et al. The role of the endosymbiotic Wolbachia bacteria in the pathogenesis of river blindness. Science 2002;295(5561):1892-5.
29. Schwartz EC, Huss R, Hopkins A, Dadjim B, Madjitoloum P, Hénault C, et al. Blindness and visual impairment in a region endemic for onchocerciasis in the Central African Republic. British Journal of Ophthalmology 1997;81(6):443-7.
30. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
31. Shibuya K, Bernard C, Ezzati M, Mathers CD. Global burden of onchocerciasis in the year 2000: summary of methods and data sources. Epidemiology and Burden for Disease (EBD), Global Programme on Evidence for Health Policy (GPE), World Health Organization. www.who.int/healthinfo/statistics/bod_onchocerciasis.pdf (accessed 8 March 2014).
32. Simonsen PE. Filariases. In: Cook GC editor(s). Manson's Tropical Diseases. 22nd Edition. Philadelphia: Saunders-Elsevier, 2009:1477-513.
33. Tamarozzi F, Halliday A, Gentil K, Hoerauf A, Pearlman E, Taylor MJ. Onchocerciasis: the role of Wolbachia bacterial endosymbionts in parasite biology, disease pathogenesis, and treatment. Clinical Microbiology Reviews 2011;24(3):459-68.
34. Taylor HR. Applying new design principles to the construction of an illiterate E chart. American Journal of Optometry and Physiological Optics 1978;55(5):348-51.
35. Taylor MJ, Hoerauf A, Townson S, Slatko BE, Ward SA. Anti-Wolbachia drug discovery and development: safe macrofilaricides for onchocerciasis and lymphatic filariasis. Parasitology 2014;141(1):119-27.
36. Wanji S, Tendongfor N, Nji T, Esum M, Che JN, Nkwescheu A, et al. Community-directed delivery of doxycycline for the treatment of onchocerciasis in areas of co-endemicity with loiasis in Cameroon. Parasites and Vectors 2009;2(1):39.
37. Whitworth JA, Gilbert CE, Mabey DM, Morgan D, Foster A. Visual loss in an onchocerciasis endemic community in Sierra Leone. British Journal of Ophthalmology 1993;77(1):30-2.
38. World Health Organization. Onchocerciasis and its control. Report of a WHO expert committee on onchocerciasis control. World Health Organization Technical Report Series 1995;852:1-104.
39. World Health Organization. ICD-10 International Statistical Classification of Diseases and Related Health Problems. World Health Organization Edition. Geneva, Switzerland: WHO 2010; Vol. 2.
40. World Health Organization. Onchocerciasis fact sheet No. 374 [updated March 2015]. www.who.int/mediacentre/factsheets/fs374/en/ (accessed 9 December 2015).
41. World Health Organization. Water-related diseases. Onchocerciasis. www.who.int/water_sanitation_health/diseases/oncho/en/ (accessed 9 December 2015).
42. Winthrop KL, Furtado JM, Sliva JC, Resnikoff S, Lansingh VC. River blindness: an old disease on the brink of elimination and control. Journal of Global Infectious Diseases 2011;3(2):151-5.
43. Zimmerman PA, Dadzie KY, De Sole G, Remme J, Alley ES, Unnasch TR. Onchocerca volvulus DNA probe classification correlates with epidemiologic patterns of blindness. Journal of Infectious Diseases 1992;165(5):964-8.
44. Abegunde AT, Ahuja RM, Okafor NJ. Doxycycline plus ivermectin versus ivermectin alone for treating onchocerciasis. Cochrane Database of Systematic Reviews 2014, Issue 6. [DOI: 10.1002/14651858.CD011146]